Dr. Maliekel studies the intersection of cancer treatment and other medical conditions, especially in patients who have multiple health issues. She examines cases like those of individuals with acute promyelocytic leukemia (APL) who are also living with HIV, showcasing how they can successfully manage both diseases. Her research also includes treating patients with thymoma—a type of tumor—alongside chronic conditions such as myotonic dystrophy, by employing chemotherapy and radiation effectively. Additionally, Dr. Maliekel investigates how certain clotting factors behave in cancer patients, enhancing the understanding of their risks and treatment options.
Key findings
In a case study of a patient with both HIV and acute promyelocytic leukemia, the patient has remained cancer-free for 40 months after treatment.
Dr. Maliekel successfully treated a woman with thymoma and myotonic dystrophy using chemotherapy and radiation, resulting in her being tumor-free for 19 months.
Out of 39 cancer patients studied for activated-protein-C resistance, 5 (13%) showed resistance, indicating a potential risk factor for bleeding complications.
In a case involving a woman with acquired hemophilia, the use of recombinant factor VIIa helped control bleeding and manage a pseudotumor, leading to 18 months without complications.
Frequently asked questions
Does Dr. Maliekel study HIV-related conditions?
Yes, she examines how patients with HIV can also manage other conditions like blood cancers.
What treatments has Dr. Maliekel researched for cancer patients?
She has researched chemotherapy and radiation treatments for thymoma and acute promyelocytic leukemia, among others.
Is Dr. Maliekel's work relevant to patients with blood clotting issues?
Yes, her studies on activated-protein-C resistance and bleeding management offer insights into treatments for patients with such issues.
What is myotonic dystrophy, and does Dr. Maliekel study it?
Myotonic dystrophy is a chronic muscle disorder, and yes, she focuses on treating it in patients with comorbid conditions.
Publications in plain English
Acute promyelocytic leukemia and HIV-1 infection: case report and review of the literature.
2004
American journal of hematology
Kudva GC, Maliekel K, Richart JM, Batanian JR, Grosso LE +2 more
Plain English This study examines a 27-year-old man with HIV who developed a type of blood cancer called acute promyelocytic leukemia (APL). The patient received a combination of treatments, including certain chemotherapy drugs and continued HIV treatment, and he has been cancer-free for 40 months since his diagnosis. This matters because it highlights how patients with both HIV and APL can achieve remission and effectively manage their conditions.
Who this helps: This helps patients with both HIV and blood cancers, as well as their doctors.
Thymoma and myotonic dystrophy: successful treatment with chemotherapy and radiation: case report and review of the literature.
2002
Chest
Kudva GC, Maliekel K, Kim HJ, Naunheim KS, Stolar C +2 more
Plain English This study looks at a 42-year-old woman with myotonic dystrophy who was also diagnosed with thymoma, a type of tumor. She was treated with a mix of chemotherapy and radiation, and after 19 months she is still free of the tumor, though her myotonic dystrophy has not changed. It’s significant because she is the first patient successfully treated for this combination of conditions using this approach, adding to the limited existing cases in medical literature.
Who this helps: This helps patients with thymoma and myotonic dystrophy, as well as their doctors.
Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia.
1997
Haemophilia : the official journal of the World Federation of Hemophilia
Maliekel K, Rana N, Green D
Plain English This study looked at how recombinant factor VIIa can help manage a large blood clot-like growth in an elderly woman with acquired hemophilia, a condition that makes it hard to stop bleeding. Despite having high levels of antibodies that made standard treatments ineffective, the use of recombinant factor VIIa allowed the doctors to control the bleeding and successfully remove the growth. After the treatment, the woman's bleeding issues improved, and she has had no complications for 18 months, which is very encouraging.
Who this helps: This helps patients with acquired hemophilia and their doctors by providing a viable treatment option for severe bleeding episodes.
Activated-protein-C resistance in cancer patients.
1997
Haemostasis
Green D, Maliekel K, Sushko E, Akhtar R, Soff GA
Plain English This study looked at how often cancer patients have resistance to activated protein C, which is important for blood clotting. Out of 39 patients with advanced cancer, 5 (13%) showed resistance, while none of the healthy control group did. This resistance was linked to higher levels of certain blood clotting factors, but it didn't directly predict whether a patient would have blood clots.
Who this helps: This information benefits doctors and researchers working with cancer patients, helping them understand blood clotting risks.
Ganesh C Kudva D Green John M Richart Jacqueline R Batanian Leonard E Grosso Marcia Sokol-Anderson Paul J Petruska Han J Kim Keith S Naunheim Cary Stolar
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.